Journal of Antimicrobial Chemotherapy (1999) 44, 179-192
© 1999 The British Society for Antimicrobial Chemotherapy
In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic
Biosearch Italia S.p.A., Via R. Lepetit, 34-21040 Gerenzano (Varese), Italy
BI 397 (formerly A-A-1) is a semisynthetic derivative of the teicoplanin-like glycopeptide A40926. It was more active in vitro against staphylococci (including some teicoplanin-resistant strains) than teicoplanin and vancomycin. Against streptococci (including penicillin-resistant strains) BI 397 has activity comparable with that of teicoplanin and better than vancomycin. BI 397, when administered to rats by the iv route, gives high and long lasting blood levels. It shows excellent activity in models of acute septicaemia in immunocompetent and neutropenic mice. In a rat staphylococcal endocarditis model it is as effective as teicoplanin and vancomycin at reducing bacterial loads in the heart, but at lower dosages and with a reduced number of daily treatments compared with the two glycopeptide controls. BI 397 is highly efficacious in clearing penicillin-susceptible and -resistant pneumococci from lungs of immunocompetent and neutropenic rats. The data from these studies show that BI 397 combines an excellent in-vitro antibacterial activity with favourable pharmacokinetic behaviour resulting in potent in-vivo activity.
* Corresponding author. Tel: +39-2-96474-243; Fax: +39-2-96474-238; E-mail: gcandiani{at}biosearch.it
Present address. Hoechst Marion Roussel, 102, Route de Noisy,
F-93235 Romainville Cedex, France.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Marbury, J. A. Dowell, E. Seltzer, and M. Buckwalter Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment J. Clin. Pharmacol., April 1, 2009; 49(4): 465 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bailey and K. M. Summers Dalbavancin: A new lipoglycopeptide antibiotic Am. J. Health Syst. Pharm., April 1, 2008; 65(7): 599 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Attwood and K. L. LaPlante Telavancin: A novel lipoglycopeptide antimicrobial agent Am. J. Health Syst. Pharm., November 15, 2007; 64(22): 2335 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Alduina, L. L. Piccolo, D. D'Alia, C. Ferraro, N. Gunnarsson, S. Donadio, and A. M. Puglia Phosphate-Controlled Regulator for the Biosynthesis of the Dalbavancin Precursor A40926 J. Bacteriol., November 15, 2007; 189(22): 8120 - 8129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Nicolau, H. K. Sun, E. Seltzer, M. Buckwalter, and J. A. Dowell Pharmacokinetics of dalbavancin in plasma and skin blister fluid J. Antimicrob. Chemother., September 1, 2007; 60(3): 681 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Goldstein, D. C. Draghi, D. J. Sheehan, P. Hogan, and D. F. Sahm Bactericidal Activity and Resistance Development Profiling of Dalbavancin Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1150 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Bowker, A. R. Noel, and A. P. MacGowan Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system J. Antimicrob. Chemother., October 1, 2006; 58(4): 802 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Jones, H. S. Sader, T. R. Fritsche, P. A. Hogan, and D. J. Sheehan Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J. Clin. Microbiol., July 1, 2006; 44(7): 2622 - 2625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-W. Lin, P. L Carver, and D. D DePestel Dalbavancin: A New Option for the Treatment of Gram-Positive Infections Ann. Pharmacother., March 1, 2006; 40(3): 449 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lin, K. Smith, L. M. Ednie, and P. C. Appelbaum Antipneumococcal Activity of Dalbavancin Compared to Other Agents Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5182 - 5184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Buckwalter and J. A. Dowell Population Pharmacokinetic Analysis of Dalbavancin, a Novel Lipoglycopeptide J. Clin. Pharmacol., November 1, 2005; 45(11): 1279 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lin, K. Credito, L. M. Ednie, and P. C. Appelbaum Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide Antimicrob. Agents Chemother., February 1, 2005; 49(2): 770 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jabes, G. Candiani, G. Romano, C. Brunati, S. Riva, and M. Cavaleri Efficacy of Dalbavancin against Methicillin-Resistant Staphylococcus aureus in the Rat Granuloma Pouch Infection Model Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1118 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Leighton, A. B. Gottlieb, M. B. Dorr, D. Jabes, G. Mosconi, C. VanSaders, E. J. Mroszczak, K. C. M. Campbell, and E. Kelly Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers Antimicrob. Agents Chemother., March 1, 2004; 48(3): 940 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lefort, J. Pavie, L. Garry, F. Chau, and B. Fantin Activities of Dalbavancin In Vitro and in a Rabbit Model of Experimental Endocarditis Due to Staphylococcus aureus with or without Reduced Susceptibility to Vancomycin and Teicoplanin Antimicrob. Agents Chemother., March 1, 2004; 48(3): 1061 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. C. Goldstein, D. M. Citron, C. V. Merriam, Y. Warren, K. Tyrrell, and H. T. Fernandez In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1968 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Anderegg, D. J. Biedenbach, and R. N. Jones Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive Activity J. Clin. Microbiol., June 1, 2003; 41(6): 2795 - 2796. [Full Text] [PDF]
|
|